Abstract
BackgroundThere are currently no effective systemic therapies of primary Sjögren’s syndrome (pSS); however, open label series have suggested that rituximab may be beneficial for systemic and glandular manifestations.ObjectivesTo estimate clinical...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have